24 February 2017 | News | By BioSpectrum Bureau
Taipei firm works to cure cancer through mushrooms
Singapore: Taipei based Zhenjuntang Biotechnology aims to cure cancer through a mushroom -stout camphor fungus, also called "niu zhang zhi" in Chinese. Since its establishment in 2009, the company has dedicated itself to the artificial cultivation of the mushroom, its pharmacological extraction and detailed analysis and the various potential clinical applications it offers.
To provide further impetus to its efforts the company has plans to launch a tumor research center in Xiamen and open three chain stores in the cities of Zhangzhou, Quanzhou and Shishi and three cultivation facilities in Xiamen, Sichuan and Anhui.
Moving forward, Zhenjuntang Biotech aims to establish a standardized research and supply chain specialized for the development and cultivation of stout camphor fungus, with DNA profiling and genome sequence mapping for visible traceability.
The company also plans to work closely with medical research centers in both Taiwan and China to actively develop and manufacture a series of target medicines for the treatment of severe cancers, such as leukemia, liver and gastric cancer. By utilizing the benefits of stout camphor fungus to the fullest, Zhenjuntang Biotech hopes to deliver a brighter future that patients can look forward to.